

Gilead – a bridge to a healthier world

Access to healthcare varies across the globe

Gilead is a champion of health equity, working to transform lives on a **global scale**, operating in **157 low- and middle-income countries**

Pioneers in access

Gilead pioneers in delivering life-changing medications to the people and places that need them most

Gilead builds innovative, sustainable programs that enable long-term access for millions of people to life changing treatments for HIV, viral hepatitis and invasive fungal infections, and future transformational medicines



Gilead is committed to helping end the HIV epidemic



A healthier world for all


Gilead's work in LLMICs is vital to Gilead's vision of creating a healthier world for all people – no matter where they live or who they are

Gilead's access strategy for HIV prevention

Access to long-acting HIV PrEP options, is critical for people around the world who need additional choices to reduce their chances of acquiring HIV

Gilead's PrEP access strategy was developed in consultation with more than **100** global health stakeholders – it is based on **4 pillars** that guide every step of the access strategy:


Deliver with speed



Sufficient volume to meet demand



Prices to support access in LLMICs



Implementation through partners on the ground



Together, we deliver healthcare access and choice to the people and places that need it most

Gilead – our commitment to PrEP

Gilead is committed to broad, sustainable access to lenacapavir (LEN) for PrEP, in high-incidence, resource-limited countries

Access support via a two-part strategy



Voluntary Licensing to Generic Companies


Royalty-free agreements signed with **6** manufacturers to make and supply generic versions of LEN for PrEP in **120** high-incidence **LLMICs**



Direct Provision by Gilead

Partnerships with the Global Fund and PEPFAR to deliver Gilead-supplied LEN for PrEP, at no profit to Gilead.

Prioritising registrations that cover **18** countries representing **70%** of the HIV burden in **LLMICs**



Providing access to injectable HIV prevention for to up to **2 million** people over next **3 years**

Abbreviations: LMIC, low- and middle-income country; PEPFAR, President's Emergency Plan for AIDS relief; PrEP, pre-exposure prophylaxis.

Reference: <https://www.gilead.com/responsibility/global-health-and-access/access-in-low--and-middle-income-countries/access-strategy-for-long-acting-prep> Accessed November 2025

Lenacapavir is an investigational agent in most countries. Where it has not been approved by the local regulatory agency it has not been determined to be safe and efficacious.

This leaflet was developed and funded by Gilead Sciences Inc.

Job code: GPS-UNB-0036. Date of preparation: November 2025

